Qiming's Portfolio Company InventisBio Lists on STAR Market
/PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the...
Source: prnewswire.com
Page 8 - Venus Medtech News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Venus Medtech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Venus Medtech Today - Breaking & Trending Today
Global Percutaneous Aortic Valve Implantation Market Anticipated to Garner $13,454.6 Million in Revenue, Rising at a CAGR of 13.9% over the Estimated Timeframe, 2021 to 2028 [160-Pages]
The global percutaneous aortic valve implantation market is expected to see striking growth by 2028, due to the increasing incidences of cardiovascular disorders among people globally. The North
Source: finanznachrichten.de
![Global Vascular Disease Devices Market Estimated to Surpass $22,610.3 Million and Grow at 6.9% CAGR in the 2021-2028 Timeframe [175-Pages] - Vimarsana News](https://mma.prnewswire.com/media/997523/Research_Dive_Logo.jpg?p=twitter){kind=logo}
Global Vascular Disease Devices Market Estimated to Surpass $22,610.3 Million and Grow at 6.9% CAGR in the 2021-2028 Timeframe [175-Pages]
/PRNewswire/ -- Research Dive has added a new report to its offering titled, "Vascular Disease Devices Market by Product (Stents, Balloons, Catheters,...
Source: prnewswire.com
Filling gap in market: VenusP-Valve™ approved by China's NMPA
/PRNewswire/ -- On July 11, 2022, VenusP-ValveTM, Venus Medtech's in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, was...
Source: prnewswire.com
Filling gap in market: VenusP-Valve approved by China's NMPA
HANGZHOU, China, July 13, 2022 /PRNewswire/ -- On July 11, 2022, VenusP-ValveTM, Venus Medtech's in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, was approved by China's National Medical Products Administration (NMPA) for the treatment of severe pulmonary regurgitation (3+) in patients after congenital heart defects (CHD) procedure with native right ventricular outflow tract (RVOT). The approval has made VenusP-ValveTM the first TPVR product to be marketed in China, marking another milestone following its CE MDR approval. As the first self-expanding...
Source: singaporestar.com